GoAmerica up 21% in pre-market trading after Q2 earnings

GoAmerica, Inc. (Nasdaq:GOAM) was up 21% to $8.70 in pre-market trading following the 8:00 a.m. ET release of second-quarter earnings. | Nasdaq: GOAM |Comment

Thermage CEO expects acquisition to save costs, improve opportunities

Thermage, Inc. (Nasdaq:THRM) CEO Steve Fanning said the company bought Reliant because the two companies, which make anti-aging devices, are complimentary and will allow for greater opportunities... | Nasdaq: THRM |Comment

AspenBio Pharma shares rise on start of clinical trials

AspenBio Pharma, Inc. (Nasdaq:APPY) announced Thursday it had begun independent clinical trials for its AppyScore appendicitis diagnostic test, moving the shares of the pharmaceutical company up. | Nasdaq: APPY |Comment

CollaGenex Pharmaceuticals to be acquired by Galderma Laboratories

Shares of CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) are surging to a 52-week high on high volume in pre-market trading after the specialty pharmaceutical company reported early this morning... | CGPI |Comment

Merit Medical Systems (MMSI): The heart of the matter

For many aging boomers combating heart disease, it is in Merit Medical Systems (Nasdaq: MMSI), a maker of disposable medical products used in radiology and cardiology, that they will find an... | MMSI |Comment

Usana Health Sciences CEO confident about future

Usana Health Sciences, Inc. (Nasdaq: USNA) CEO Myron Wentz said the embattled company remains confident in its business outlook and the investment opportunity it provides. The multi-level marketing... | USNA |Comment

Natus Medical Inc.: Hear it first

Cute ticker, serious business: Natus Medical Inc. (Nasdaq: BABY) makes products used to treat and detect medical disorders in newborns and infants. | BABY |Comment

Genoptix, Inc.: A bone-crusher?

Read why Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, is emerging as a stand-out not only in its sector, but among small caps as a whole. | GXDX |Comment

USANA Health Sciences soars on SEC decision

USANA Health Sciences, Inc. (Nasdaq: USNA) shares are soaring after the Securities and Exchange Commission said it will not take action against the nutritional and personal-care products maker. | USNA |Comment

Bio-Imaging Technologies, Inc.: Picture perfect

Over the past 17 years, Bio-Imaging Technologies, Inc. (Nasdaq: BITI) has become the largest independent provider of the equipment and technology needed for medical imaging used in the... | BITI |Comment

Hythiam, Inc. to turn CF positive, recorded strong revenues

Hythiam, Inc. (Nasdaq: HYTM) said it expects it will turn cash flow positive in 2008 and it achieved record revenues for the month of December 2007. | HYTM |Comment

Sequenom climbs on N.Y. approval of product

Sequenom, Inc. (Nasdaq: SQNM) shares are climbing after the maker of genetic analysis products announced that the state of New York approved the first noninvasive prenatal test based on... | SQNM |Comment

Exactech: We age, it grows

This company makes joint replacement products that orthopedic surgeons use to repair or replace knees, shoulders or hips, along with related services to help joint tissue regenerate. In other... | Comment

Adolor Corp. inks exclusive agreement with Pfizer

Adolor Corp. (Nasdaq: ADLR), a provider of prescription pain management products, said this morning that it made an exclusive deal with Pfizer Inc. (NYSE: PFE) to develop and commercialize novel... | ADLR |Comment

Obagi Medical Products, Inc.: Hey, but you look great

The skin care industry thrives on the softening of mean facts: a wrinkle becomes a soft tissue deficit. Obagi Medical Products, Inc. (Nasdaq: OMPI) says it can repair these epidermal shortcomings... | OMPI |Comment

AngioDynamics, Inc.: Good for your wealth

Everyone from soccer moms wanting varicose veins erased to aging patients needing their clogged arteries cleared has found solutions from AngioDynamics, Inc. The 19-year-old company makes a wide... | ANGO |Comment

Kensey Nash makes first bone void filler shipment

Medical technology company Kensey Nash Corp. (Nasdaq: KNSY) said this morning that it shipped its first product kit of its bone void filler OsseoFit Porous Tissue Matrix to Biomet Sports Medicine,... | KNSY |Comment

Physicians Formula Holdings reports better-than-expected Q3 earnings

Shares of Physicians Formula Holdings, Inc. (Nasdaq: FACE) are climbing higher today after the cosmetics company reported better-than-expected third-quarter earnings after Monday’s close. | FACE |Comment

Abiomed slips after wider Q2 loss

Abiomed, Inc. (Nasdaq: ABMD) shares are down in pre-market trading after the medical products and services provider announced a wider second-quarter loss of $9.4 million, or $0.29 per share, worse... | ABMD |Comment

Caliper Life Sciences records Q3 loss penny wider than Street's forecast

Caliper Life Sciences, Inc. (Nasdaq: CALP), a provider of tools and services for drug discovery and life sciences research, reported this morning that it clocked a net loss for the third quarter,... | CALP |Comment

CryoLife higher as Q3 profit rises

Shares of CryoLife Inc. (Nasdaq: CRY) are higher following news before the start of trading that maker of biomaterials and implantable medical devices reported a rise in third-quarter profit | CRY |Comment

Incyte beats Q3 revenue estimates

Incyte Corp. (Nasdaq: INCY) shares are slightly up after the drug developer reported third-quarter revenue $6.7 million, above analyst estimates of $6.4 million and compared with $7.3 million a... | INCY |Comment

Hythiam reports findings from Prometa Treatment Program

Hythiam, Inc. (Nasdaq: HYTM) today reported a statistically significant reduction in methamphetamine cravings with its Prometa Treatment Program, a primary study endpoint from a randomized,... | HYTM |Comment

Abaxis, Inc.: Catering to both crowds

Reporting record results is not usually how a quarter is supposed to turn out for a company that says it was seeking to repair the weakest links in its operations. But that’s exactly what this... | ABAX |Comment

Sector Watch: Joint replacement

Like a fine wine, life gets better with age, but sometimes parts need replacing to keep your engine going. Baby boomers are getting a new lease on life—in the form of hip and knee replacements,... | OFIX |Comment

LCA-Vision Q3 revenues shy of Street, lowers guidance

Shares of LCA-Vision Inc. (Nasdaq: LCAV) are sinking this morning after the provider of laser vision correction services under the LasikPlus brand reported revenues shy of expectations and lowered... | LCAV |Comment

Cardica to initiate secondary offering

Shares of Cardica, Inc. (Nasdaq: CRDC) are edging down in pre-market trading after the manufacturer of anastomotic systems used to perform coronary artery bypass surgery said it will offer 1.5... | CRDC |Comment

Staar Surgical to acquire Canon's interest in JV

Staar Surgical Company (Nasdaq: STAA), a manufacturer of ophthalmic products, reported this morning that it will acquire the interests of all other shareholders in Canon Staar Co., Inc., a joint... | STAA |Comment

Javelin Pharmaceuticals: House of pain relief

Javelin Pharmaceuticals is all about controlling pain. The company now has three products it is planning to introduce in upcoming quarters, and approvals would not only ease patient suffering but... | JAV |Comment

Transcend Services books strong quarter

Transcend Services, Inc. (Nasdaq: TRCR), a provider of medical transcription services to the U.S. health-care market, reported strong third quarter results this morning. | TRCR |Comment

Radiation Therapy Services to be acquired for $1.1B

Shares of Radiation Therapy Services, Inc. (Nasdaq: RTSX) spiked in pre-market trading after the radiation therapy services firm said it will be acquired by Vestar Capital Partners for $32.50 per... | RTSX |Comment

PetMed Express reports strong Q2 earnings

Pet Pharmacy PetMed Express, Inc. (Nasdaq: PETS) this morning reported robust earnings for its second fiscal quarter, ahead of analysts’ estimates. | PETS |Comment

Angiotech Pharmaceuticals falls to 52-week low, expects Q3 loss

Shares of Angiotech Pharmaceuticals Inc. (Nasdaq: ANPI) have sunk to a 52-week low following news before the start of trading that the company expects a third-quarter net loss and has lowered its... | ANPI |Comment

Kensey Nash swings to Q1 loss

Medical technology company Kensey Nash Corp. (Nasdaq: KNSY) said it swung to a loss in its first quarter of fiscal year 2008 due to pre-tax charges for the acceleration of stock awards and the... | KNSY |Comment

Nektar Therapeutics' 'Exubera' dropped by Pfizer

Shares of Nektar Therapeutics Inc. (Nasdaq: NKTR) sunk to a 52-week low in pre-market trading this morning after Pfizer disclosed in an earnings report today that the pharmaceutical juggernaut will... | NKTR |Comment

Fonar Corp. receives six orders from Health Diagnostics

Fonar Corp. (Nasdaq: FONR) inventor of MR Scanning, said this morning that Health Diagnostics, LLC has ordered six Fonar Upright Multi-Position MRIs. | FONR |Comment

Medtox Scientific down after missing Q3 revenue estimates

Medtox Scientific, Inc. (Nasdaq: MTOX) shares are sagging after the medical products seller and provider of medical services announced before the opening that its third-quarter revenue rose to... | MTOX |Comment

Via Pharmaceuticals Inc. higher, receives OK for drug tests

Shares of Via Pharmaceuticals, Inc. (Nasdaq: VIAP) have added more than 20% following news before the opening that an independent board gave the green light for continued studies of the company’s... | VIAP |Comment

Synta Pharmaceuticals to collaborate with GlaxoSmithKline

Synta Pharmaceuticals Corp. (Nasdaq: SNTA) said this morning that it will collaborate with GlaxoSmithKline (NYSE: GSK) to develop and commercialize STA-4783, a small-molecule, oxidative stress... | GSK |Comment

QLT Inc. falls to 52-week low, buys eye-care company

Shares of QLT Inc. (Nasdaq: QLTI) have hit a new 52-week low on news before the start of trading that the Canadian pharmaceutical company will buy eye-care technology maker ForSight Newco II for... | QLTI |Comment

Cantel Medical CEO: Expansion through acquisitions and internal development

Cantel Medical Corp. (NYSE: CMN) CEO Scott Jones said the health-care products maker will expand its business segments through internal development and acquisitions. He said the company expects to... | CMN |Comment

Pre-market: Hansen Medical jumps on Cramer's comments

Shares of Hansen Medical, Inc. (Nasdaq: HNSN) popped in pre-market trading after theStreet.com's Jim Cramer said late Thursday that the company “is a buy on any pull back.” | HNSN |Comment

Generex Biotechnology receives patent for metered dose spray

Generex Biotechnology Corp. (Nasdaq: GNBT), which specializes in drug delivery for metabolic diseases through the inner lining of the mouth, said this morning that it was awarded a patent for its... | GNBT |Comment

Hanger Orthopedic Group: On the cutting edge

In a lethargic health sector, this small cap is a standout. With an innovative device that helps stroke survivors and others walk, sales and earnings for the company are set to accelerate. | HGR |Comment

Javelin Pharmaceuticals granted patent

Javelin Pharmaceuticals Inc. (AMEX: JAV) shares are up after the firm announced before the opening that it was granted a patent that will strengthen protection of PMI-150, its postoperative pain... | JAV |Comment

SIGA Technologies' smallpox drug shows 100% protection

SIGA Technologies, Inc. (Nasdaq: SIGA) announced after the close Wednesday that its lead smallpox drug, ST-246, demonstrated 100% protection against death in cynomolgus monkeys showing signs of... | SIGA |Comment

CollaGenex Pharmaceuticals trial for treatment of rosacea fails

Investors are sending shares of CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI) spiraling downward today after the specialty pharmaceutical company said that results of a Phase 2 study of a drug... | CGPI |Comment

Emergent BioSolutions inks $448M contract

Shares of Emergent BioSolutions Inc. (NYSE: EBS) shot up out of the gate this morning after the biopharmaceutical company reported this morning that it has signed a three year contract with the... | EBS |Comment

Emisphere Technologies settles with Eli Lilly for $18M

Biopharmaceutical company Emisphere Technologies, Inc. (Nasdaq: EMIS) said this morning that it has agreed to accept $18 million from Eli Lilly and Co. to settle pending litigation between the two... | EMIS |Comment

Phase 1 trial initiated on Pharmacopeia's drug

Pharmacopeia, Inc. (Nasdaq: PCOP), which discovers and develops small molecule therapeutics, announced this morning that Schering-Plough has begun a Phase 1 clinical trial with a compound developed... | PCOP |Comment